This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Onsi W. Kamel, MD

Arch Dermatol. 1997;133(7):903-904.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PATIENTS WHO are immunocompromised are at an increased risk for developing malignant lymphoma. Until recently, immunodeficiency-related lymphomas have been described in 3 main groups of patients: solid organ transplant recipients who receive immunosuppressive therapy to prevent organ rejection,^1,2 patients with congenital immunodeficiency syndromes,^3,4 and patients with the acquired immunodeficiency syndrome.⁵ However, during the last few years, several investigators have reported^6-21 the occurrence of immunodeficiency-related lymphomas in yet a fourth clinical setting: patients who are treated with immunomodulatory therapy for rheumatologic diseases. Although there are several clinicopathologic features associated with immunodeficiency-related lymphomas, the most characteristic finding is the presence of the Epstein-Barr virus (EBV) in the neoplastic lymphoid cells. See also page 867

In this issue of the ARCHIVES, Paul and colleagues²² report the occurrence of an EBV-associated lymphoma in a patient receiving methotrexate therapy for psoriasis. The lymphoma that this patient developed is similar to . . . [Full Text PDF of this Article]

Author Affiliations
Department of Pathology St John's Hospital 800 E Carpenter St Springfield, IL 62769

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?